University Systems Among Those Choosing Forte Research To Centrally Manage Research
Forte Research Systems announced that six leading clinical research institutions selected the company?s enterprise research system last year.
Forte Research Systems announced that six leading clinical research institutions—from university systems, hospitals and cancer groups--selected the company’s enterprise research system, last year. Forte also offers a specialized clinical trial management systems (CTMS).
The following organizations chose OnCore Enterprise Research system to centrally manage clinical research operations, with half implementing the system across multidisciplinary research groups:
- University of Colorado Denver
- University of Hawaii Cancer Center
- Baylor College of Medicine
- Hoosier Oncology Group
- Fox Chase Cancer Center
- Northside Hospital
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
